Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition

Leuk Lymphoma. 2021 Jul;62(7):1761-1764. doi: 10.1080/10428194.2021.1881504. Epub 2021 Feb 12.

Authors

Jie Wang¹, Takuya Osada², Michael A Morse¹, Frank Calzone³, Hai Yan⁴, Dung Thai⁴, H Kim Lyerly²

Affiliations

¹ Department of Medicine, Duke Cancer Institute, Durham, NC, USA.
² Department of Surgery, Duke Cancer Institute, Durham, NC, USA.
³ ImmPACT-Bio, Camarillo, CA, USA.
⁴ REMD Biotherapeutics, Camarillo, CA, USA.

PMID: 33576297
DOI: 10.1080/10428194.2021.1881504

No abstract available

Publication types

Letter

MeSH terms

Glucagon
Humans
Hyperglycemia* / chemically induced
Neoplasms*
Phosphatidylinositol 3-Kinases / genetics
Phosphatidylinositol 3-Kinases / metabolism
Receptors, Glucagon / genetics
Signal Transduction

Substances

Receptors, Glucagon
Glucagon